Follitropin Alpha versus Follitropin Beta in IVF/ICSI Cycle: A Retrospective Cohort Study
Jing-Xian Cao,Jing-Yan Song
DOI: https://doi.org/10.2147/dddt.s479700
IF: 4.3188
2024-09-27
Drug Design Development and Therapy
Abstract:Jing-Xian Cao, 1 Jing-Yan Song 2, 3 1 Gynecology, Binzhou Hospital of Traditional Chinese Medicine, Binzhou, People's Republic of China; 2 The First Clinical College, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China; 3 Reproductive Center of Integrated Medicine, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China Correspondence: Jing-Yan Song, The First Clinical College, Shandong University of Traditional Chinese Medicine, Reproductive Center of Integrated Medicine, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, No. 42, Wen Hua Xi Road, Lixia District, Jinan, 250011, People's Republic of China, Tel +86-0531-68617921, Email Purpose: The purpose of this study was to compare the efficacy of Follitropin alpha (Gonal-F) and Follitropin beta (Puregon) on cumulative live birth rate (CLBR), defined as the percentage of the number of patients who delivered for the first time in a single ovarian stimulation cycle and the number of patients in all oocyte retrieval cycles. Methods: A retrospective cohort study including 2864 infertile patients who underwent ovarian stimulation with Puregon (group A, n=1313) and Gonal-F (group B, n=1551) was conducted between July 2015 and June 2021 at a university-affiliated reproductive medicine center. Reduce potential confounding factors between groups, propensity scores and multivariable logistic regression analyses were estimated to obtain unbiased estimates of outcomes. The primary outcome was the difference in CLBR between the two groups. Results: Each group identified 1160 individuals after propensity score matching (PSM). Baseline characteristics were similar between groups after PSM. The total gonadotrophin (Gn) dose (2400 vs 2325), p=0.038) and cost of Gn usage (5327.9¥ vs 7547.2¥, p< 0.001) between the Puregon and Gonal-F groups were statistically significant. Nevertheless, the pregnancy outcomes between the two groups were comparable after fresh embryo transfer and subsequent frozen-thawed embryo transfer. Additionally, there was also no difference observed in the primary outcome of CLBR (52.8% vs 55.7%, p=0.169). Multivariable regression analysis revealed that the type of Gn was not associated with CLBR (p = 0.912). Conclusion: Gonal-F may be a reasonable option for infertile patients who are hesitant to receive more Gn dosage injections. Furthermore, Puregon can eliminate unneeded anxiety and expenses while also administering more flexibility. Taken together, these findings could well be utilized in everyday clinical practice to better inform patients when deciding on an ovarian stimulation strategy. Keywords: cumulative live birth rate, follitropin alpha, follitropin beta, in vitro fertilization, propensity score matching The use of Gn has experienced human menopausal gonadotropins, urinary-derived gonadotropins, and recombinant human follicle-stimulating hormone (r-FSH), and is widely used in the process of in vitro fertilization and embryo transfer (IVF-ET). 1 In 1988, recombinant DNA technology was used to develop the gonadotropin for higher purity gonadotropin, 2 Gonal-F was successfully developed by transforming subunits of human Follitropin beta genes coding α and β into expression vectors into Chinese hamster ovary cells, 3 licensed in Europe in 1996. In 1997, Puregon, another recombinant human FSH, was approved. 4 Advocation of recombinant DNA technology has promoted the development of high purity and high-specific r-FSH, according to the composition subunit, composed of two non-covalently connected, different glycoproteins, respectively designed as α subunit and β base. These α and β subunits were encoded by different genes, 92 and 111 amino acids, respectively. There are currently three r-FSH products on the market, FSH α, FSH β and FSH δ, and a fourth product, FSH ε, is reported to be under development. In a systematic review and meta-analysis, 7 randomized controlled trials (RCTs) were included to compare the effects of personalized r-FSH δ with traditional r-FSH α/β in gonadotropin releasing hormone (GnRH) antagonist IVF/ICSI cycles. Neither group demonstrated significant differences in clinical pregnancy rates, ongoing pregnancy rates, or live birth rates. 5 r-FSHα (Gonal-F) and r-FSHβ (Puregon) in IVF/intracytoplasmic sperm injection (ICSI) are widely used, with many disclosed, safe and clinical evidence and experience. 6,7 The two preparations are similar to pituitary and urinary derived FSH, but show slight differences in carbohydrate side chain structure, containing more alkali and less acidic hormones than urinary -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal